Management of the statin-intolerant patient

Current Treatment Options in Cardiovascular Medicine

Volumn 11, Issue 4, 2009, Pages 263-271

  Smiley III, William H ^a   Khan, Bobby V ^a   Sperling, Laurence S ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ATORVASTATIN; BILE ACID SEQUESTRANT; C REACTIVE PROTEIN; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; CREATINE KINASE; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; UBIDECARENONE;

AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG MUSCLE LEVEL; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ISCHEMIC HEART DISEASE; LIVER FUNCTION TEST; LOW FAT DIET; MONOTHERAPY; MUSCLE DISEASE; MUSCLE SPASM; MUSCLE WEAKNESS; MYALGIA; NONHUMAN; PAIN ASSESSMENT; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

EID: 67651097495     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-009-0027-3     Document Type: Review

References (24)

1. Baigent C, Keech A, Kearney PM, et al.: Cholesterol Treatment Trialists' (CTT) Collaborators: Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomized trials of statins. Lancet 2005, 366:1267-1278.
2. Davidson MH, Robinson JG: Safety of aggressive lipid management. J Am Coll Cardiol 2007, 49:1753-1762.
3. McKenney JM, Davidson MH, Jacobson TA, Guyton JR: Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force. Am J Cardiol 2006, 97(Suppl 1):S89-S94.
4. Scott RS, Lintott CJ, Wilson MJ: Simvastatin and side effects. N Z Med J 1991, 104:493-495.
5. Bruckert E, Hayem G, Dejager S, et al.: Mild to moderate muscular symptoms with high - dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther 2005, 19:403-414.
6. Ballantyne CM, Herd A, Ferlic L, et al.: Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360:7-22.
7. Phillips PS, Hass RH, Bannykh S, et al.: Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002, 137:581-585.
8. Marcoff L, Thompson PD: The role of coenzyme Q10 in statin-associated myopathy: A systematic review. J Am Coll Cardiol 2007, 49:2231-2237.
9. Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme Q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409-1412.
10. Oh J, Ban MR, Miskie BA, et al.: Genetic determinants of statin intolerance. Lipids Health Dis 2007, 6:7.
11. Hansen KE, Hildebrand JP, Ferguson EE, et al.: Outcomes in 45 patients with statin-associated myopathy. Arch Intern Med 2005, 165:2671-2676.
12. Matalka MS, Ravnan MC, Deedwania PC: Is alternate daily dose of atorvastatin effective in treating patients with hyperlipidemia? The Alternate Day Versus Daily Dosing of Atorvastatin Study (ADDAS). Am Heart J 2002, 144:674-677.
13. Backes JM, Moriarty PM, Ruisinger JF, Gibson CA: Effects of once weekly rosuvastatin among patients with a prior statin intolerance. Am J Cardiol 2007, 100:554-555.
14. Backes JM, Venero CV, Gibson CA, et al.: Effectiveness and tolerability of every-other-day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008, 42:341-346.
15. Athyros VG, Tziomalos K, Kakafika AI, et al.: Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008, 101:483-485.
16. Jenkins DJA, Kendall CWC, Marchie A, et al.: Effects of a dietary portfolio of cholesterol-lowering foods vs lovastatin on serum lipids and C-reactive protein. JAMA 2003, 290:502-551.
17. Canner PL, Berge KG, Wenger NK, et al.: Fifteen year mortality in Coronary Drug Project patients: Long term benefit with niacin. J Am Coll Cardiol 1986, 8:1245-1255.
18. Brown G, Albers JJ, Fisher LD, et al.: Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990, 323:1289-1298.
19. Zema MJ: Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia. Am J Ther 2005, 12:306-310.
20. Xydakis AM, Guyton JR, Chiou P, et al.: Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia. Am J Cardiol 2004, 94:795-797.
21. Rubins HB, Robins SJ, Collins D, et al.: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 1999, 341:410-418.
22. Scott R, O'Brien R, Fulcher G, et al.: Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome. Diabetes Care 2009, 32:493-498.
23. McKenney JM, Farnier M, Lo K-W, et al.: Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia. J Am Coll Cardiol 2006, 47:1584-1587.
24. Whitney EJ, Krasuski RA, Personius BE, et al.: A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 2005, 142:95-104.